Surgical treatment for primary papillary thyroid cancer: a Meta-analysis / 临床耳鼻咽喉头颈外科杂志

OBJECTIVE@#To assess and compare the two procedures, total thyroidectomy (TT) and partial thyroidectomy (PT), for papillary thyroid cancer in terms of associated injuries, postoperative complication, recurrence rate and survival, so as to provide a reference and basis for surgical procedure option of this disease.@*METHOD@#Strictly specified into the exclusion criteria, the combination of computer retrieval and manual retrieval and retrieval systems such as CNKI, Wang Fan, PubMed, central, CBM database. Total thyroidectomy and partial thyroidectomy for the treatment of patients with thyroid papillary cancer related literature were compared, with the retrieval time until December 31, 2013.@*RESULT@#According to the retrieval strategy 4630 literatures were found, and 20 witch matched the exclusion criteria were left, all were retrospective study. TT and PT group of recurrent laryngeal nerve injury rate are 5.9%, 2.0% respectively [OR = 0.39, 95% CI (0.17 - 0.90), P < 0.05], TT and PT group of parathyroid injury rate are respectively 4.9%, 0.8% respectively [OR = 0.23, 95% CI (0.08 - 0.68), P < 0.01]. The TT group of 10 years survival rate is 95.24% - 100%, and the PT group is 96.8% - 99.2% [OR = 0.03, 95% CI (0 - 0.34), P < 0.01]. Unstaged, unstaged TT group' postoperative recurrence rate is 4.7%, while PT group is 12.6% [OR = 3.21, 95% CI (1.57 - 6.57), P < 0. 01]. Postoperative recurrence of stage I TT group and PT group are 4.9%, 7.8% respectively [OR = 3.82, 95% CI (1. 07-13.66) P < 0.05]; The rate of stage II TT group is 0.5%, while the rate of PT group is 15.9% [OR = 17.23, 95% CI (4.03 - 73.73), P < 0.01].@*CONCLUSION@#Different methods of primary thyroid papillary carcinoma surgical treatment can all obtaina good survival, but the rate of laryngeal recurrent nerve injury and parathyroid injury caused by partal throidectomy is relatively lower. As a result, partial thyroidectomy can be a good choice for early stage thyroid papillary carcinoma.

Expression of cancer stem cell marker USP22 in laryngeal squamous cell carcinoma / 中华耳鼻咽喉头颈外科杂志

<p><b>OBJECTIVE</b>To investigate the expression of cancer stem cell marker USP22 in laryngeal squamous cell carcinoma (LSCC) and clinical implications.</p><p><b>METHODS</b>The expression of USP22 was detected by immunohistochemistry in LSCC tissues of 64 cases and squamous epithelium tissues beside carcinoma of 26 cases (control). The correlation of USP22 expression with various clinicopathologic factors was evaluated with the single factor analysis.</p><p><b>RESULTS</b>The expression levels of USP22 in LSCC and control were 57.8% and 19.2% (P < 0.05). Clinicopathological analysis showed that USP22 expression level had a relationship with clinical stage, T stage, and lymph node metastasis (P < 0.05), but not with gender, age, smoking and differentiation (P > 0.05). Survival analysis showed that patients with high USP22 expression had significantly poorer outcome compared with patients with low USP22 expression. The survival was related to clinical stage, T stage, and lymph node metastasis, but not with age, sex, and smoking (P > 0.05).</p><p><b>CONCLUSIONS</b>The expression of USP22 is significantly increased in LSCC, which correlates with the malignant degree, invasion, metastasis and prognosis of LSCC. USP22 may be served as a new candidate molecular marker and therapeutic target of LSCC.</p>